Advanced lung adenocarcinoma (LUAD) patient with EGFR mutations benefited from multiline combination targeted therapies after osimertinib (AZD9291) resistance: a case report

Introduction

Osimertinib is a well-known third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that is highly selective for common EGFR-activating mutations as well as the EGFR T790M mutation in advanced non-small cell lung cancer (NSCLC) patients, but most patients will inevitably develop resistance. As previously reported (1), the resistance mechanisms to osimertinib encompass on-target molecular alterations, such as the well-known EGFR C797S resistance mutation, and off-target molecular alterations, such as the high-frequency MET amplification. Due to tumor heterogeneity, more novel resistance mechanisms were continually detected, including multiple resistance mutations (2). However, there’s no further clear-cut therapeutic option to date for these individuals yet. In this study, we have reported an advanced Chinese lung adenocarcinoma (LUAD) patient who progressed on osimertinib benefited from multiline combination target-therapy and obtained a long-term PFS. We present the following article in accordance with the CARE reporting checklist (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-510/rc).

Case presentation

A 70-year-old, female, never-smoker was referred to our clinic with a two-month history of persistent cough with sputum in September 2016. No past medical history was identified. Her father died of lung cancer, her mother died of intestinal cancer, her sister died of endometrial cancer. The treatment history and the images of the patient were shown in Figure 1. Positron emission tomography (PET) scan showed consolidation in the right upper lobe and multiple small pulmonary nodules in both lungs (Figure 1B). Transbronchial biopsy was performed on the right lung and histopathology confirmed moderate to poorly differentiated adenocarcinoma. Immunohistochemically, tumor cells in the main part were positive for CK7, TTF1, Napsin A, Ki 67 (40% +), and negative for p63, CD56, and Syn. According to the 8th edition of the tumor, node and metastasis (TNM) classification of lung cancer, this patient was classified as stage IV NSCLC.

Figure 1 Timeline and clinical response of the patient’s treatment. (A) Diagram illustrating the various treatments the patient received including PFS (in months) and the specific time points of next-generation sequencing performed on tissue and blood samples (indicated by asterisks). (B) PET scan before treatment. (C) CT imaging after 11 months of osimertinib treatment. (D) CT imaging after 7 months of combination treatment of osimertinib and cabozantinib/capmatinib. SD was achieved. (E) CT imaging after 10 months of combination treatment of osimertinib and cabozantinib/capmatinib. (F) CT imaging after 6 months of combination therapy of pemetrexed and bevacizumab. (G) CT imaging after 5 months of combination therapy of brigatinib and cetuximab. PR, partial response; OR, overall response; SD, stabled disease; PFS, progression-free survival; PET, positron emission tomography; CT, computed tomography.

Next-generation sequencing (NGS) identified EGFR exon 19 deletion (19 del) with the allele frequency (AF) 84.74%, and EGFR amplification at a copy number (CN) of 16.9. The first-generation EGFR TKI gefitinib was administered (Figure 1A, Table 1). At disease progression after 5 months’ treatment, NGS analysis of broncho-fiberscope rebiopsy revealed EGFR T790M mutation, with the retention of 19 del. Osimertinib was immediately initiated at 80 mg daily, then added to 140 mg after 7 months. The best response was partial response (PR) and the serum level of blood tumor marker carcinoembryonic antigen (CEA) was significantly reduced after two months’ treatment (Figure 2). After 11 months of progression-free survival (PFS), the patient experienced disease progression in her right upper lung lesion with pleural effusion (PE) (Figure 1C). Then, the blood and tissue-based NGS was performed and both detected MET amplification, in addition to EGFR exon 19 del in February 2018 (Table 1). Combination therapy of osimertinib (100 mg, bid) and cabozantinib (40 mg, bid) was administrated to the patient. Cabozantinib was switched to capmatinib (250 mg, bid) one month later due to the side effects of diarrhea and anorexia and increased CEA (Figure 2). Stabled disease (SD) was achieved and PFS was 10 months (Figure 1D). Pulmonary computed tomography (CT) revealed increase in lung nodules size and an increased volume of PE, with a new flake high-density shadow within the inferior lobe of the right lung in December 2018 (Figure 1E).

Figure 2 CEA levels during treatment. The normal range of CEA is 5 ng/mL (indicated by a dashed black line). CEA, carcinoembryonic antigen.

To screen for new treatment targets, NGS was performed on broncho-fiberscope rebiopsy samples in December 2018 and detected the emergence of acquired mutations EGFR S784Y (AF: 9.72%) and EGFR L799Q (AF: 9%), together with EGFR C797S c.2390_2391delinsCT (AF: 10.79%) and all in cis with EGFR T790M (AF: 23.01%), and retention of EGFR 19 del (AF: 19.64%). The patient received combination therapy of pemetrexed and bevacizumab, then observed a decrease in the primary lung mass two cycles later (from 27.5×28.5 to 22.5×26.5 mm). PR was achieved. After 6 months of PFS, follow-up CT scan demonstrated a wider septal thickening of the right lung, as well as an increase and partial enlargement of mediastinal and right hilar lymph nodes, indicating progressive disease (PD) (Figure 1F).

Tissue biopsy-based NGS was performed again in July 2019 and showed the same genetic alteration as before. Consequently, the patient received combination therapy of brigatinib (brigatinib initiated at 80 mg once daily for one week and increased by 40 mg/day every one week of treatment, and maintenance dose was 200 mg once daily) and cetuximab (300 mg biweekly for the first 2 cycles, and maintenance dose was to 400 mg biweekly). She achieved a SD and the PFS was lasting 18 months with no adverse events other than mild fatigue transaminase elevation. During the treatment, she received molecular analysis on hydrothorax twice, five months later (Dec. 2019) and one year later (Jul. 2020) respectively (Table 1). The results were as below respectively: EGFR S784Y (AF: 4.28% vs. 1.04%), EGFR L799Q (AF: 3.87% vs. 1.32%), EGFR C797S (c.2390_2391delinsCT) (AF: 53.16% vs. 13.64%), EGFR C797S (c.2389T>A) (AF: 0 vs. 1.26%), EGFR T790M (AF: 57.36% vs. 14.93%), EGFR 19 del (AF: 51.17% vs. 38.52%). The S784Y, L799Q, and C797S (c.2389T>A) mutations exist in trans with C797S (c.2390_2391delinsCT) but all in cis with T790M (Figure 3). The patient died at the end of 2020, due to a heart problem, and her overall survival was 51 months.

Figure 3 Next generation sequencing result of patient’s hydrothorax in July 2020. (A) Sequencing reads of EGFR mutations visualized by the IGV. (B) Allelic context of different EGFR mutations. EGFR, epidermal growth factor receptor; IGV, Integrative Genomics Viewer.

All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the editorial office of this journal.

Discussion

There is no effective care for heavily-treated and osimertinib-resistance metastatic LUAD patients yet, especially multiple resistance mutations (1). Multiple resistance mutations have been reported previously in very few cases similar to our patient, but no therapeutic regimen was reported, except for the idea of combination therapy (3). Here, we report an advanced LUAD patient with osimertinib-resistance who received subsequently combination targeted therapy and obtained a long-term clinical benefit.

In our case, a MET amplification was initially detected after resistance to osimertinib. As previously reported, some preclinical or clinical studies have suggested that MET amplification is likely to be a key mechanism underlying acquired resistance to osimertinib (4,5). Combination therapy with EGFR-TKI and a MET inhibitor should be considered for these patients. However, most case reports or clinical studies were related to the combination therapy of first-generation EGFR-TKI and a MET inhibitor (5-8), and the effectiveness of treatments was variable. In this study, a combination therapy of osimertinib and cabozantinib/capmatinib was administrated to our patient, while only osimertinib plus capmatinib showed better effectiveness and tolerance, achieving SD with PFS of 10 months. The result suggested that combination therapy of osimertinib and capmatinib may be a potential choice for osimertinib-resistant patient with MET amplification.

We first reported the emergence of novel acquired mutations EGFR S784Y and L799Q, in addition to EGFR triple mutation (19 del/T790M/C797S) after progression on osimertinib plus capmatinib. EGFR S784F/P have been reported previously insensitive to gefitinib and erlotinib (9-12). Here, the S784Y and L799Q mutations exist in trans with C797S (c.2390_2391delinsCT) but all in cis with T790M, which indicated T790M plus cis-S784Y/L799Q may be a potential resistance mechanism to osimertinib.

A combination therapy of brigatinib and cetuximab, which potentially overcoming EGFR triple mutations (activating mutation, T790M, and cis-C797S) (13-15), was administrated to the patient and achieved a substantial clinical benefit with a PFS of 18 months. To our best knowledge, it’s the first report that combined targeted therapy of brigatinib and cetuximab could be an effective treatment strategy to improve survival outcomes in patients who acquire EGFR 19 del-T790M-cis-C797S-S784Y-L799Q mediated resistance to osimertinib.

Taken together, the idea of combination therapy with EGFR-TKI and MET inhibitor for the patient harboring co-mutations of MET amplification and EGFR exon 19 del is feasible, and osimertinib plus capmatinib should be suggested as a potential effective choice. Also, the combination therapy of brigatinib and cetuximab may overcome the novel acquired EGFR (S784Y/L799Q/T790M) mutations, as well as EGFR triple mutations (activating mutation, T790M, and cis-C797S), but further study is needed.

Acknowledgments

The authors thank Mr. Chanhe Li, Mr. Zhiqiu Chen, and Dr. Chunxiao Pan from Burning Rock Biotech for their help in sequencing.

Funding: This research was supported by the National Natural Science Foundation of China (No. 81803055).

Footnote

Reporting Checklist: The authors have completed the CARE reporting checklist. Available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-510/rc

Peer Review File: Available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-510/prf

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-510/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013). Written informed consent was obtained from the patient for the publication of this case report and accompanying images. A copy of the written consent is available for review by the editorial office of this journal.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Leonetti A, Sharma S, Minari R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer 2019;121:725-37. [Crossref] [PubMed]
2. Ou SI, Cui J, Schrock AB, et al. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer 2017;108:228-31. [Crossref] [PubMed]
3. Fairclough SR, Kiedrowski LA, Lin JJ, et al. Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort. Exp Hematol Oncol 2019;8:24. [Crossref] [PubMed]
4. Le X, Puri S, Negrao MV, et al. Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC. Clin Cancer Res 2018;24:6195-203. [Crossref] [PubMed]
5. Wang Q, Yang S, Wang K, et al. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. J Hematol Oncol 2019;12:63. [Crossref] [PubMed]
6. Deng H, Wang L, Chen X, et al. Erlotinib plus tivantinib versus erlotinib alone in patients with previously treated stage IIIb/IV non-small-cell lung cancer: A meta-analysis based on randomized controlled trials. Medicine (Baltimore) 2020;99:e20596. [Crossref] [PubMed]
7. Yu HA, Goldberg SB, Le X, et al. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer 2021;22:601-6. [Crossref] [PubMed]
8. Sequist LV, Han JY, Ahn MJ, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol 2020;21:373-86. [Crossref] [PubMed]
9. Wu JY, Yu CJ, Chang YC, et al. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-21. [Crossref] [PubMed]
10. De Pas T, Toffalorio F, Manzotti M, et al. Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations. J Thorac Oncol 2011;6:1895-901. [Crossref] [PubMed]
11. Masago K, Fujita S, Irisa K, et al. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I). Jpn J Clin Oncol 2010;40:1105-9. [Crossref] [PubMed]
12. Cossu-Rocca P, Muroni MR, Sanges F, et al. EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma. Am J Cancer Res 2015;6:71-83. [PubMed]
13. Wang Y, Yang N, Zhang Y, et al. Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy. J Thorac Oncol 2020;15:1369-75. [Crossref] [PubMed]
14. Wang X, Zhou L, Yin JC, et al. Lung Adenocarcinoma Harboring EGFR 19del/C797S/T790M Triple Mutations Responds to Brigatinib and Anti-EGFR Antibody Combination Therapy. J Thorac Oncol 2019;14:e85-8. [Crossref] [PubMed]
15. Uchibori K, Inase N, Araki M, et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun 2017;8:14768. [Crossref] [PubMed]